Media Articles
OBT Declared a “Well-deserved Double Award Winner” at the Fourth Annual Thames Valley SME Growth 100 Awards
March 01 2023: OBT has been honoured with two prestigious awards: the ‘Tech Company of the Year’ and the ‘Special Recognition Award’, at The Business Magazine’s fourth annual Thames Valley SME Growth 100 Awards. These awards celebrate the region's most active small and medium-sized enterprises (SMEs) that have grown significantly in the past year. OBT was declared a double-award winner in recognition of its successful growth in 2022, which saw the company double both its turnover and headcount, and apply these additional resources to establish new R&D and clinical partnerships with major players in the international biotechnology space while simultaneously strengthening and extending its drug development pipeline.
This article is taken from the Business Magazine 01 March 2023. View the full press release here.
March 01 2023: OBT has been honoured with two prestigious awards: the ‘Tech Company of the Year’ and the ‘Special Recognition Award’, at The Business Magazine’s fourth annual Thames Valley SME Growth 100 Awards. These awards celebrate the region's most active small and medium-sized enterprises (SMEs) that have grown significantly in the past year. OBT was declared a double-award winner in recognition of its successful growth in 2022, which saw the company double both its turnover and headcount, and apply these additional resources to establish new R&D and clinical partnerships with major players in the international biotechnology space while simultaneously strengthening and extending its drug development pipeline.
This article is taken from the Business Magazine 01 March 2023. View the full press release here.
|
|
|
OBT Tops the Thames Valley SME 100 Growth Index 2022
September 28 2022: The annual Thames Valley SME Growth 100 index recognises and promotes the region’s high-growth small and medium-sized enterprises, and is ranked by year on year growth. Independent, privately-owned companies, headquartered in the region, that have grown their turnover significantly in the past year are included. We are pleased that OBT has topped the 2022 index with our substantial growth of 154.5%.
This article is taken from the Business Magazine 28 September 2022.
September 28 2022: The annual Thames Valley SME Growth 100 index recognises and promotes the region’s high-growth small and medium-sized enterprises, and is ranked by year on year growth. Independent, privately-owned companies, headquartered in the region, that have grown their turnover significantly in the past year are included. We are pleased that OBT has topped the 2022 index with our substantial growth of 154.5%.
This article is taken from the Business Magazine 28 September 2022.
How Immune Priming Could Make More Patients Eligible for Immunotherapy
September 14 2022: “Targeting CD205-expressing cells may not only remove cancer cells, but also allow the immune system to reset and restart in an immunogenic direction by selectively depleting regulatory cells, and preventing T cell activation and proliferation."
Read more here about how OBT is developing a dual action antibody-drug conjugate (ADC), targeting the CD205 protein on a) cancer immune inhibitory cells to reverse immune suppression, and b) the cancer cells directly.
This article is taken from EuropeanBiopharmaceutical Review October 2022, pages 78-80. © Samedan Ltd.
September 14 2022: “Targeting CD205-expressing cells may not only remove cancer cells, but also allow the immune system to reset and restart in an immunogenic direction by selectively depleting regulatory cells, and preventing T cell activation and proliferation."
Read more here about how OBT is developing a dual action antibody-drug conjugate (ADC), targeting the CD205 protein on a) cancer immune inhibitory cells to reverse immune suppression, and b) the cancer cells directly.
This article is taken from EuropeanBiopharmaceutical Review October 2022, pages 78-80. © Samedan Ltd.
Immunotherapies Expose and Exploit Cancer’s Varied Weaknesses
March 18 2021: “If we could understand why some people reengage their immune system after receiving chemotherapy, while others don’t, we could think about how to combine various therapeutic modalities and in what sequence”, says Christian Rohlff, PhD, CEO of Oxford BioTherapeutics. Read more here about how OBT uses proprietary immuno-oncology technology and antibody-drug conjugates to develop novel therapeutics that can reengage the immune system to destroy cancer cells.
March 18 2021: “If we could understand why some people reengage their immune system after receiving chemotherapy, while others don’t, we could think about how to combine various therapeutic modalities and in what sequence”, says Christian Rohlff, PhD, CEO of Oxford BioTherapeutics. Read more here about how OBT uses proprietary immuno-oncology technology and antibody-drug conjugates to develop novel therapeutics that can reengage the immune system to destroy cancer cells.